Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer
- 13 August 2011
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 130 (2), 681-689
- https://doi.org/10.1007/s10549-011-1703-z
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2008
- Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research NetworkBreast Cancer Research and Treatment, 2007
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor—Positive Breast CancerJournal of Clinical Oncology, 2004
- Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast CancerJournal of Clinical Oncology, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older WomenJournal of Clinical Oncology, 2001
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996